Health

Veeva sells AI flat, and IQVIA's seven-month clock starts the test

Veeva priced Vault AI at 10 percent of a subscription with unlimited usage, betting model costs fall faster than adoption, while IQVIA's seven-month rollout puts a clock on the standardization it needs first.

Vincent JiangVincent Jiang · 2 min read
Share
Veeva CEO Peter Gassner on stage at the Veeva Summit in Boston presenting the Vault AI and Falcon Agents roadmap to an audience.
1 / 5Slide 1 of 5
Veeva CEO Peter Gassner presents the Vault AI and Falcon Agents roadmap at the Veeva Summit in Boston, where the flat AI pricing and the IQVIA deal were announced.

Veeva Systems+0.45% — Veeva Systems, up 0.45 percent today put a price on AI this week, and the price is the point. At its Boston summit on October 20 and 21, the life-sciences software house said Vault AI, the agentic layer now live across its applications, will cost 10 percent of a Vault subscription, 5 percent in the first year, with unlimited usage 1. Its CEO Peter Gassner quipped that no one ever moved the industry forward by counting tokens 1.

The customer stops paying for tokens

Token-metered AI makes the customer carry the inference bill; a flat percentage makes Veeva carry it, for 750,000 people working in Vault on an average day and roughly 250,000 reports run daily 1. The bet is that model costs fall faster than usage rises, on a business that has held gross margin at about 75 percent for eight straight quarters 12.

Standardization with a clock on it

The other half of the summit was an order book. IQVIA+0.03% — IQVIA, up 0.03 percent today, the world's largest contract research organization with about 94,000 staff, will adopt four Veeva modules (CTMS, eTMF, Study Startup and Site Connect) as its enterprise standard within seven months, with every new IQVIA study on the platform from the third quarter of 2027 13.

Around 30,000 IQVIA staff will ultimately touch the software; IQVIA runs roughly 2,000 trials at any time 1. Gassner's thesis is the shipping container: an industry that cannot standardize cannot automate. Falcon agents, which file documents and draft clinical study reports, work only on standardized data, which is why Biogen−0.84% — Biogen, down 0.84 percent today and IQVIA are standardizing first 1.

Gross margin has held at 75 percent for eight straight quarters

7475767778Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26The flat-fee bet starts here
Data
Gross margin (%)
Q3 '2475.1
Q4 '2474.9
Q1 '2577.1
Q2 '2575.3
Q3 '2575.4
Q4 '2574.5
Q1 '2675
Q2 '2675
Gross margin has held at 75 percent for eight straight quarters2

What decides it

The market has priced in a lot: Veeva closed at $322.55 on October 22, a 52-week high, up 44.5 percent this year, at 51.6 times trailing earnings against 23.0 for the S&P 500 45. Third-quarter guidance of $932 million to $935 million implies about 15 percent growth, slower than the 17.6 percent just posted, and deferred revenue slipped to $1.31 billion from $1.49 billion at January 31 42. Two dates test the bet: IQVIA reports on October 27, and Veeva holds its investor day on November 5 34.

What happens next

IQV

Whether the seven-month Veeva standardization rollout stays on track

The case for

Flat pricing removes the token-metering brake on AI adoption across 750,000 daily Vault users.

The case against

At 51.6 times trailing earnings against 23.0 for the S&P 500 after a 44.5 percent gain this year, a lot is priced in.

  1. Tue Oct 27IQVIA reports quarterly results.
  2. Thu Nov 5Veeva investor day. How Veeva frames the Vault AI cost bet behind the flat fee
  3. Q3 2027Every new IQVIA study moves onto Veeva's platform.

Get our follow-up when these land

Free. We'll email you when we publish on IQVIA, and send our free weekday newsletter. Unfollow in one click.

Loading IQV…

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Intuitive Surgical to pay $450 million to settle hospitals' antitrust suit; revenue per procedure falls 3-5%

    Intuitive settled the hospitals' instrument-servicing antitrust case for $450 million, then disclosed its own 3-5% per-procedure price cut for 2027. The recurring revenue that carries 84% of sales now faces cheaper instruments on two fronts, just as US procedure growth slows to 10%.

    Health

    A compounded Zepbound recall hands Eli Lilly its exhibit as a fifth of US GLP-1 users take copies

    Apothecary Pharma could not guarantee the safety of 22 lots of compounded tirzepatide. With roughly a fifth of U.S. GLP-1 users on compounded copies, the October 29 and November 4 earnings prints will price what the copycat channel costs Lilly and Novo.

    Health

    Abridge carries a $6.69 billion mark on trials showing its scribe saves 22 minutes a day

    The independent trials have landed next to the expansion metrics: 22 minutes a day is what a health system can actually count. That caps the per-encounter price and moves the value to clinical content and workflow, where Wolters Kluwer and Doximity trade.

    Health

    Doximity put Wolters Kluwer's UpToDate inside its Ask tool for health systems, and named no price

    Doximity's rival claims died on October 16; on October 20 it licensed Wolters Kluwer's UpToDate into Ask with no price attached, while a securities class action and an EBITDA-cutting AI bill press on the stock.

    Health

    Molina Healthcare beat estimates and held guidance, yet its profit fell 53% and the stock sank about 5%

    Adjusted EPS of $0.89 beat estimates and full-year guidance held, and after-hours sellers still took the Medicaid insurer down about 5%. The fight over whether Medicaid margins have turned moves to Thursday's 8 a.m. call.

    Health

    Tempus AI tops 80% sensitivity on 12 lung biomarkers but withholds the specificity number

    An AI panel reading routine lung slides flagged all 12 NSCLC biomarkers above 80% sensitivity across 60,459 cases. The number Tempus withheld, specificity, decides whether the flag trims lab workload or sells more of its own tests, and it lands six days before the Q3 print.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.